Signature STb O+ — The flagship liquid-biopsy profile.
Comprehensive genomic profiling from blood. The fullest picture OnKommon offers.
Signature STb O+ is our comprehensive genomic profile from blood — the fullest liquid-biopsy picture OnKommon offers. It is designed to leave no clinically-relevant stone unturned: broad driver coverage, fusions, copy-number, the complete immune & PGx profile, mutational signatures, and the widest reach for clinical-trial matching.
The fullest liquid-biopsy CGP
Every intelligence layer populated — clonal architecture, synergy, subtype, immune readiness, trial matching, and access.
- Comprehensive gene coverage: SNVs, InDels, fusions, CNVs
- Full immune profile: TMB, MSI, MMR
- Mutational signatures: COSMIC-style analysis
- PGx panel: 35-gene pharmacogenomics profile
- Complete Blueprint Care report: Every intelligence layer populated
CGP means reading a large, curated set of cancer genes in depth.
Combining several kinds of signal — point mutations, insertions and deletions, gene fusions, copy-number changes, and genome-wide markers — in a single test.
It is the difference between finding the obvious drivers and understanding the whole tumour. CGP gives your oncologist the complete picture — not just what's driving the cancer, but how it might respond, what it might resist, and what options exist beyond the obvious.
Complete. Comprehensive. Unmatched.
Everything you need for the fullest liquid-biopsy picture — all in one test.
Comprehensive Gene Coverage
SNVs, InDels, fusions and copy-number variation across a large curated set of cancer genes.
Full Immune Profile
TMB, MSI, MMR — the complete set, analytically robust for immunotherapy decision-making.
Mutational Signatures
COSMIC-style signatures — what has been driving the mutations in your cancer.
Pharmacogenomics (PGx)
The 35-gene Pharmacogenomics & Drug-Response Panel — how you metabolise key drugs.
All Six Intelligence Layers
Clonal architecture, synergy, subtype, immune readiness, trial matching, and access — fully populated.
Three reasons to choose the comprehensive profile.
CGP is the right choice when you need the fullest picture and the widest options.
Immunotherapy Eligibility
TMB and MSI are central to your decision. CGP gives you the complete immune profile with analytical confidence.
Limited Standard Options
Standard options are limited and you want the widest trial-matching reach — including early-phase targeted trials.
Deepest Analysis
You want the deepest computational analysis behind your plan — every intelligence layer fully populated.
CGP unlocks the most complete Blueprint Care report.
Every intelligence layer populated, the fullest therapy matrix, immune-readiness index, resistance forecast, and the broadest set of matched trials.
Fullest Therapy Matrix
Every actionable alteration matched to drugs, biosimilars, and trials — with the widest reach for off-label and cross-tumor options.
Immune-Readiness Index
Complete immune profile with ImmunoLens™ — a clear readout of whether the immune system can recognise your tumour.
Resistance Forecast
CloneTrace™ maps clonal architecture — distinguishing trunk from branches — so your doctor knows what to target and what might escape.
Broadest Trial Matching
TrialGraph™ matches your exact profile to recruiting studies — including early-phase targeted trials and combination opportunities.
This is precision oncology at its most complete. Still authored and signed by KPCIRC's molecular tumour board — so a qualified human team, not software, stands behind the report.
Beyond standard options.
At CGP breadth, TrialGraph™ matches your exact profile to recruiting studies — including early-phase targeted trials — and SynerGx™ evaluates rational drug combinations for future enrolment if standard therapies are exhausted.
Confirmed at consultation.
Confirmed at consultation, with clear guidance on whether CGP is the right investment for your case.
The science behind this
Comprehensive genomic profiling from blood is validated and increasingly guideline-endorsed for advanced cancer.
Study 1 · Validated blood CGP across many cancers
A cfDNA-based comprehensive genomic profiling assay was validated across more than 7,500 tests and 30,000+ variants spanning 300+ genes and 30+ cancer types.
Study 2 · Guideline-endorsed when tissue is limited
NCCN and ESMO recommend ctDNA profiling as an alternative or complement to tissue; ASCO recommends blood cfDNA as the specimen of choice for comprehensive profiling in advanced breast cancer.
Study 3 · Broader testing, more matched therapy
Adding plasma genotyping to tissue in advanced lung cancer increased detection of targetable alterations and the number of patients who received matched therapy.
The words you will see, in plain language.
What we DO
- Deliver the fullest liquid-biopsy CGP with immune & PGx profile
- Populate every intelligence layer and the widest trial match
- Report mutational signatures and copy-number changes
- Feed the most complete, MTB-signed Blueprint Care report
What we DON'T do
- Diagnose or decide treatment on its own
- Rule out disease from a negative result
- Guarantee a matched trial will have a place
- Guarantee drug availability, approval, cover, or benefit
Signature STb O+ is a genomic (DNA-based) test offered for use by qualified healthcare professionals. It is intended to support — not replace — clinical judgement, and must be interpreted alongside your full clinical history, other investigations, and applicable guidelines.
- • A result is not a diagnosis and does not by itself decide treatment.
- • A "not detected" or normal result does not rule out cancer or a genetic change.
- • Not all cancers release enough DNA into blood to be detected.
- • The test does not guarantee access to any medicine, its regulatory approval, insurance cover, or that a therapy will work.
- • Sample-collection kits are for use by qualified phlebotomists only — not for self-testing or self-sampling.
- • Confirmatory testing may be required.
Regulatory status (India). OnKommon's registration of its genomic tests as in-vitro diagnostic (IVD) medical devices with the Central Drugs Standard Control Organisation (CDSCO) is in progress (IVD class pending). Sequencing and variant calling are performed by an accredited laboratory partner (College of American Pathologists — CAP-accredited; ISO 15189) following international guidelines (ACMG/AMP/ASCO/CAP) using a CE-IVD certified variant database. The OnKommon interpretation engine is provided for research and decision-support use. Marketing follows the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954 and applicable Indian advertising standards.
Take the next step
Every OnKommon page offers three ways forward. Choose the one that fits where you are today.
Book a free Blueprint Consultation
A no-obligation conversation with our care team, arranged through KPCIRC, to map your situation and the right starting point.
Book now →Free WhatsApp guidance (Signal)
A 4-hour triage reply to your first question, at no cost.
Start WhatsApp triage →